{"transactions":[{"id":3694573,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":161007,"kind":"person","name":"Binder-Scholl Gwendolyn Knowlton","position":1,"cik":"0001662116","reported_name":"Binder-Scholl Gwendolyn Knowlton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"American Depositary Shares representing Ordinary Shares","published_at":"2019-01-16T21:31:56.000Z","date":"2019-01-14","kind":"sale","acquired":false,"shares":1514,"price":5.3694,"value":8129.2716,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ADSs were obtained from the exercise of approximately 25% of an RSU-style share option covering ordinary shares of the Issuer granted on January 12, 2018 and which vested on January 12, 2019. Once vested, the RSU-style options must be exercised within a restricted period or they are forfeited. The exercise of the portion of these RSU-style share options and the sale reported in this Form 4 were effected pursuant to a Sell to Cover exercise implemented automatically in accordance with the Issuer's option plan, under which sufficient ADSs were sold by the Issuer to satisfy the Reporting Person's tax withholding obligations and associated sale costs. The residual ADSs are held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $5.21 to $5.70, inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The ADSs reported in this Column 5 represent solely those residual ADSs held by the Reporting Person which result from the Sell to Cover exercise transaction reported on this Form 4. Additionally, the Reporting Person holds RSU-style options and other options covering an aggregate of 4,979,951 ordinary shares of the Issuer."}],"balance_after":2487,"source":{"system":"sec-edgar","filing":"0001104659-19-002166","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662116/000110465919002166/a4.xml","form_type":"4"}},{"id":3801460,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":161007,"kind":"person","name":"Binder-Scholl Gwendolyn Knowlton","position":1,"cik":"0001662116","reported_name":"Binder-Scholl Gwendolyn Knowlton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"American Depositary Shares","published_at":"2018-10-02T19:58:24.000Z","date":"2018-10-01","kind":"sale","acquired":false,"shares":25000,"price":13.79,"value":344750.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ordinary shares were obtained from the exercise of share options granted on March 20, 2015. The exercise of share options and the sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 29, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $13.54 to $13.995, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-18-060128","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662116/000110465918060128/a4.xml","form_type":"4"}},{"id":3828803,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":161007,"kind":"person","name":"Binder-Scholl Gwendolyn Knowlton","position":1,"cik":"0001662116","reported_name":"Binder-Scholl Gwendolyn Knowlton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"American Depositary Shares","published_at":"2018-08-31T20:02:05.000Z","date":"2018-08-29","kind":"sale","acquired":false,"shares":25000,"price":10.25,"value":256250.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Each American Depositary Share (\"ADS\") represents six ordinary shares, nominal value GBP 0.001 per ordinary share, of the Issuer. The ordinary shares were obtained from the exercise of share options granted on March 20, 2015. The exercise of share options and the sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 29, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $10.15 to $10.41, inclusive. Upon request, the reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission full information regarding the ADSs sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-18-054853","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662116/000110465918054853/a4.xml","form_type":"4"}},{"id":4097926,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":161007,"kind":"person","name":"Binder-Scholl Gwendolyn Knowlton","position":1,"cik":"0001662116","reported_name":"Binder-Scholl Gwendolyn Knowlton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2018-01-17T17:20:51.000Z","date":"2018-01-12","kind":"grant","acquired":true,"shares":96036,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.3542 - GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable as to 24,009 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in annual installments of 24,009 Ordinary Shares on the twelfth of each January from January 12, 2020 through January 12, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable."}],"balance_after":96036,"derivative":{"exercise_price":0.0014,"underlying":"Ordinary Shares","underlying_shares":96036},"source":{"system":"sec-edgar","filing":"0001104659-18-002676","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1662116/000110465918002676/a4.xml","form_type":"4"}},{"id":4097925,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":161007,"kind":"person","name":"Binder-Scholl Gwendolyn Knowlton","position":1,"cik":"0001662116","reported_name":"Binder-Scholl Gwendolyn Knowlton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2018-01-17T17:20:51.000Z","date":"2018-01-12","kind":"grant","acquired":true,"shares":429984,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.96 based on an exchange rate of $U.S. 1.3542 - GBP1.00. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 107,496 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in monthly installments of 8,958 Ordinary Shares on the twelfth of each month from February 12, 2019 through January 12, 2022."}],"balance_after":429984,"derivative":{"exercise_price":1.3,"expiration_date":"2028-01-12","underlying":"Ordinary Shares","underlying_shares":429984},"source":{"system":"sec-edgar","filing":"0001104659-18-002676","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662116/000110465918002676/a4.xml","form_type":"4"}},{"id":4488315,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":161007,"kind":"person","name":"Binder-Scholl Gwendolyn Knowlton","position":1,"cik":"0001662116","reported_name":"Binder-Scholl Gwendolyn Knowlton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Option to purchase Ordinary Shares","published_at":"2017-01-18T17:02:15.000Z","date":"2017-01-13","kind":"grant","acquired":true,"shares":2072976,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.59 based on the closing midpoint exchange rate for the U.S. dollar on the day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable as to 518,244 Ordinary Shares on January 13, 2018 and will be exercisable as to the remainder in monthly installments of 43,187 Ordinary Shares on the thirteenth of each month from February 13, 2018 through January 13, 2021."}],"balance_after":2072976,"derivative":{"exercise_price":0.72,"expiration_date":"2027-01-13","underlying":"Ordinary Shares","underlying_shares":2072976},"source":{"system":"sec-edgar","filing":"0001104659-17-002826","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1662116/000110465917002826/a4.xml","form_type":"4"}}]}